Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: A systematic review of clinical trials

Bipolar Disorders

Volumn 13, Issue 5-6, 2011, Pages 454-465

  Sarris, Jerome ^a,b   Mischoulon, David ^c   Schweitzer, Isaac ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Adjunctive; Bipolar depression; Bipolar disorder; Depression; Mania; Mood stabilizers; Nutraceuticals; Nutrients; Omega 3

Indexed keywords

ACETYLCYSTEINE; ANTICONVULSIVE AGENT; BRANCHED CHAIN AMINO ACID; CARBAMAZEPINE; FOLIC ACID; HALOPERIDOL; INOSITOL; LITHIUM; MAGNESIUM; MINERAL; MOOD STABILIZER; NUTRACEUTICAL; OMEGA 3 FATTY ACID; QUETIAPINE; TRYPTOPHAN; VALPROIC ACID; VITAMIN;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CINAHL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; HUMAN; MEDLINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW;

AMINO ACIDS; ANTIMANIC AGENTS; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DIETARY SUPPLEMENTS; FATTY ACIDS, OMEGA-3; HUMANS; MINERALS; TREATMENT OUTCOME; VITAMINS;

EID: 80054869712     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2011.00945.x     Document Type: Review

References (66)

1. Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry 2005; 66(Suppl. 5): 11-16.
2. Culver JL, Arnow BA, Ketter TA. Bipolar disorder: improving diagnosis and optimizing integrated care. J Clin Psychol 2007; 63: 73-92.
3. Miklowitz DJ, Johnson SL. The psychopathology and treatment of bipolar disorder. Annu Rev Clin Psychol 2006; 2: 199-235.
4. Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother Psychosom 2006; 75: 139-153.
5. Kalra EK. Nutraceutical - definition and introduction. AAPS PharmSci 2003; 5: E25.
6. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Obstet Gynecol Clin North Am 2009; 36: 789-807, x.
7. Sarris J, Schoendorfer N, Kavanagh DJ. Major depressive disorder and nutritional medicine: a review of monotherapies and adjuvant treatments. Nut Rev 2009; 67: 125-131.
8. Kaplan BJ, Simpson JS, Ferre RC, Gorman CP, McMullen DM, Crawford SG. Effective mood stabilization with a chelated mineral supplement: an open-label trial in bipolar disorder. J Clin Psychiatry 2001; 62: 936-944.
9. Kaplan BJ, Crawford SG, Field CJ, Simpson JS. Vitamins, minerals, and mood. Psychol Bull 2007; 133: 747-760.
10. Popper CW. Do vitamins or minerals (apart from lithium) have mood-stabilizing effects? J Clin Psychiatry 2001; 62: 933-935.
11. Scarna A, Gijsman HJ, McTavish SF, Harmer CJ, Cowen PJ, Goodwin GM. Effects of a branched-chain amino acid drink in mania. Br J Psychiatry 2003; 182: 210-213.
12. Ille R, Spona J, Zickl M et al. "Add-On"-therapy with an individualized preparation consisting of free amino acids for patients with a major depression. Eur Arch Psychiatry Clin Neurosci 2007; 257: 222-229.
13. Dinan T, Siggins L, Scully P, O'Brien S, Ross P, Stanton C. Investigating the inflammatory phenotype of major depression: focus on cytokines and polyunsaturated fatty acids. J Psychiatr Res 2009; 43: 471-476.
14. Tassoni D, Kaur G, Weisinger RS, Sinclair AJ. The role of eicosanoids in the brain. Asia Pac J Clin Nutr 2008; 17(Suppl. 1): 220-228.
15. McNamara RK, Ostrander M, Abplanalp W, Richtand NM, Benoit SC, Clegg DJ. Modulation of phosphoinositide-protein kinase C signal transduction by omega-3 fatty acids: implications for the pathophysiology and treatment of recurrent neuropsychiatric illness. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 237-257.
16. Rao JS, Rapoport SI. Mood-stabilizers target the brain arachidonic acid cascade. Curr Mol Pharmacol 2009; 2: 207-214.
17. Chouinard G, Beauclair L, Geiser R, Etienne P. A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. Prog Neuropsychopharmacol Biol Psychiatry 1990; 14: 171-180.
18. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M. N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 2008; 8: 1955-1962.
19. Ulrich-Merzenich G, Panek D, Zeitler H, Wagner H, Vetter H. New perspectives for synergy research with the "omic"-technologies. Phytomedicine 2009; 16: 495-508.
20. Jordan SA, Cunningham DG, Marles RJ. Assessment of herbal medicinal products: challenges, and opportunities to increase the knowledge base for safety assessment. Toxicol Appl Pharmacol 2010; 243: 198-216.
21. Cohen J. Statistical Power Analyses for the Behavioral Sciences. Hillsdale: Lawrence Erlbaum Associates, 1988.
22. Berk M, Copolov DL, Dean O et al. N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 2008; 64: 468-475.
23. Chiu CC, Huang SY, Chen CC, Su KP. Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 2005; 66: 1613-1614.
24. Clayton EH, Hanstock TL, Hirneth SJ, Kable CJ, Garg ML, Hazell PL. Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 2009; 63: 1037-1040.
25. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin Psychiatry 2005; 66: 726-729.
26. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR. Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord 2010; 12: 142-154.
27. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
28. Stoll AL, Severus WE, Freeman MP et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
29. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
30. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 1978; 133: 429-435.
31. Frangou S, Lewis M, Wollard J, Simmons A. Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol 2007; 21: 435-439.
32. Hirashima F, Parow AM, Stoll AL et al. Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 2004; 161: 1922-1924.
33. Keck PE Jr, Mintz J, McElroy SL et al. Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 2006; 60: 1020-1022.
34. Duncan RE, Bazinet RP. Brain arachidonic acid uptake and turnover: implications for signaling and bipolar disorder. Curr Opin Clin Nutr Metab Care 2010; 13: 130-138.
35. Rao JS, Ertley RN, DeMar JC Jr, Rapoport SI, Bazinet RP, Lee HJ. Dietary n-3 PUFA deprivation alters expression of enzymes of the arachidonic and docosahexaenoic acid cascades in rat frontal cortex. Mol Psychiatry 2007; 12: 151-157.
36. Chalon S. Omega-3 fatty acids and monoamine neurotransmission. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 259-269.
37. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
38. Roiser J, McLean A, Ogilvie A et al. The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression. Neuropsychopharmacology 2005; 30: 775-785.
39. Chouinard G, Young SN, Annable L. A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry 1985; 20: 546-557.
40. Bell CJ, Hood SD, Nutt DJ. Acute tryptophan depletion. Part II: clinical effects and implications. Aust N Z J Psychiatry 2005; 39: 565-574.
41. Sarris J, Byrne GJ. A systematic review of insomnia and complementary medicine. Sleep Med Rev 2011; 15: 99-106.
42. Chengappa KN, Levine J, Gershon S et al. Inositol as an add-on treatment for bipolar depression. Bipolar Disord 2000; 2: 47-55.
43. Evins AE, Demopulos C, Yovel I et al. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 2006; 8: 168-174.
44. Giannini AJ, Nakoneczie AM, Melemis SM, Ventresco J, Condon M. Magnesium oxide augmentation of verapamil maintenance therapy in mania. Psychiatry Res 2000; 93: 83-87.
45. Poleszak E. Benzodiazepine/GABA(A) receptors are involved in magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep 2008; 60: 483-489.
46. Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses 2006; 67: 362-370.
47. Coppen A, Chaudhry S, Swade C. Folic acid enhances lithium prophylaxis. J Affect Disord 1986; 10: 9-13.
48. Beck A, Steer R. The Beck Depression Inventory. San Antonio: Harcourt Brace, 1987.
49. Behzadi AH, Omrani Z, Chalian M, Asadi S, Ghadiri M. Folic acid efficacy as an alternative drug added to sodium valproate in the treatment of acute phase of mania in bipolar disorder: a double-blind randomized controlled trial. Acta Psychiatr Scand 2009; 120: 441-445.
50. Folstein M, Liu T, Peter I et al. The homocysteine hypothesis of depression. Am J Psychiatry 2007; 164: 861-867.
51. Appleton KM, Rogers PJ, Ness AR. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr 2010; 91: 757-770.
52. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 2009; 28: 525-542.
53. McNamara RK. The emerging role of omega-3 fatty acids in psychiatry. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 223-225.
54. Kilbourne AM, Rofey DL, McCarthy JF, Post EP, Welsh D, Blow FC. Nutrition and exercise behavior among patients with bipolar disorder. Bipolar Disord 2007; 9: 443-452.
55. Jacka FN, Pasco JA, Mykletun A et al. Diet quality in bipolar disorder in a population-based sample of women. J Affect Disord 2011; 129: 332-337.
56. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002; 75: 492-498.
57. Molteni R, Barnard RJ, Ying Z, Roberts CK, Gomez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002; 112: 803-814.
58. Chrysohoou C, Panagiotakos DB, Pitsavos C, Das UN, Stefanadis C. Adherence to the Mediterranean diet attenuates inflammation and coagulation process in healthy adults: The ATTICA Study. J Am Coll Cardiol 2004; 44: 152-158.
59. Jacka FN, Pasco JA, Mykletun A et al. Association of Western and traditional diets with depression and anxiety in women. Am J Psychiatry 2011; 167: 305-311.
60. Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154.
61. Wozniak J, Biederman J, Mick E et al. Omega-3 fatty acid monotherapy for pediatric bipolar disorder: a prospective open-label trial. Eur Neuropsychopharmacol 2007; 17: 440-447.
62. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160: 996-998.
63. Simmons M. Nutritional approach to bipolar disorder. J Clin Psychiatry 2003; 64: 338.
64. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. Biol Psychiatry 1996; 40: 382-388.
65. Heiden A, Frey R, Presslich O, Blasbichler T, Smetana R, Kasper S. Treatment of severe mania with intravenous magnesium sulphate as a supplementary therapy. Psychiatry Res 1999; 89: 239-246.
66. Cohen BM, Lipinski JF, Altesman RI. Lecithin in the treatment of mania: double-blind, placebo-controlled trials. Am J Psychiatry 1982; 139: 1162-1164.